| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2006;82:1650-1656
© 2006 The Society of Thoracic Surgeons
a Division of Paediatric Cardiology, Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China
b Division of Cardiothoracic Surgery, Grantham Hospital, The University of Hong Kong, Hong Kong, China
Accepted for publication May 31, 2006.
* Address correspondence to Dr Cheung, Division of Paediatric Cardiology, Department of Paediatrics and Adolescent Medicine, Grantham Hospital, The University of Hong Kong, 125 Wong Chuk Hang Road, Aberdeen, Hong Kong, China. (Email: xfcheung{at}hkucc.hku.hk).
BACKGROUND: A definitive management strategy for postoperative chylothorax remains elusive. We reviewed our experience in the management of chylothorax in children after congenital heart surgery.
METHODS: The case records of 51 patients, with a median age of 11 months (range, 4 days to 19.6 years), diagnosed to have postoperative chylothorax between 1981 and 2004 were reviewed. The responses of patients to nutritional modifications, octreotide therapy, and surgical interventions were noted.
RESULTS: The prevalence of postoperative chylothorax, which developed at a median of 9 days after operation (range, 0 to 24 days), was 0.85% (51 of 5,995). Four patients died, and among the 47 survivors the median duration and total volume of chylous drainage was 15 days (range, 1 to 89 days) and 156 mL/kg (range, 3 to 6,476), respectively. The duration of chyle output was significantly longer after the Fontan-type procedures (p = 0.0006). Twenty-one patients were diagnosed between 1981 and 1999 and managed by nutritional modifications, 2 of whom required further surgical interventions. Of the 30 patients diagnosed between 2000 and 2004, 12 responded to nutritional modifications alone while 18 were started on octreotide therapy at a median of 19.5 days (range, 7 to 35 days) after the onset of chylothorax. Fifteen of the 18 (83%) patients responded to octreotide therapy at 15.3 ± 5.5 days after starting octreotide, while 3 required further surgical interventions. None developed side effects from octreotide therapy.
CONCLUSIONS: Octreotide has been incorporated into the management algorithm of postoperative chylothorax and appears to be a useful adjunctive therapy.
Related Article
Ann. Thorac. Surg. 2006 82: 1656-1657.
This article has been cited by other articles:
|
|
 |
|
  M. Itkin, G. Krishnamurthy, M. Y. Naim, G. L. Bird, and M. S. Keller Percutaneous Thoracic Duct Embolization as a Treatment for Intrathoracic Chyle Leaks in Infants Pediatrics, July 1, 2011; 128(1): e237 - e241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Nath, J. Savla, R. G. Khemani, D. P. Nussbaum, C. L. Greene, and W. J. Wells Thoracic Duct Ligation for Persistent Chylothorax After Pediatric Cardiothoracic Surgery Ann. Thorac. Surg., July 1, 2009; 88(1): 246 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Sersar Chylothorax revisited Eur J Cardiothorac Surg, June 1, 2008; 33(6): 1159 - 1159. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Pelletier Invited commentary Ann. Thorac. Surg., November 1, 2006; 82(5): 1656 - 1657. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
